Showing 4951-4960 of 5570 results for "".
- OHSU Releases Mole Mapper App to Track Potential Skin Cancershttps://practicaldermatology.com/news/ohsu-releases-mole-mapper-app-to-track-potential-skin-cancers/2458843/Oregon Health & Science University released an iPhone app it says is designed to advance melanoma research by giving users the ability to accurately measure and monitor moles, and contribute photos of how their potential trouble spots evolve over time. Called Mole Mapper, the app is free to d
- MELA Sciences Announces Election of R. Rox Anderson, MD, to Board of Directorshttps://practicaldermatology.com/news/mela-sciences-announces-election-of-r-rox-anderson-md-to-board-of-directors/2458845/R. Rox Anderson, M.D., was elected to the MELA Sciences, Inc.’s board of directors at its Annual General Meeting of Stockholders held on September 30, 2015 in Philadelphia. With Dr. Anderson's election, the MELA board of directors has increased to seven members, six of whom are independ
- Study Demonstrates Duac Significantly Reduces Inflammatory Acne Lesionshttps://practicaldermatology.com/news/study-demonstrates-duac-significantly-reduces-inflammatory-acne-lesions/2458846/Stiefel shared the findings of a head-to-head German study demonstrating that, in patients with mild-to-moderate acne vulgaris, treatment with Duac™ 3% (benzoyl peroxide 3% + clindamycin 1%) led to numerically fewer inflammatory and non-inflammatory lesions from baseline compared to treatme
- Novan Appoints Chief Financial Officer and Chief Commercial Officer to Leadership Teamhttps://practicaldermatology.com/news/novan-appoints-chief-financial-officer-and-chief-commercial-officer-to-leadership-team/2458851/Novan Therapeutics appointed two new executives from the dermatology industry to the company's leadership team. Richard Peterson has joined the company as Chief Financial Officer and Brian Johnson as Chief Commercial Officer. Mr. Peterson will be responsible for the company's financi
- New Therapeutic Skin Care Line From Galdermahttps://practicaldermatology.com/news/new-therapeutic-skin-care-line-from-galderma/2458852/Galderma Laboratories, LP, makers of Cetaphil, unveiled a new therapeutic skincare line precisely engineered for challenged skin—Excipial. It will be available over the counter and without a prescription. Excipial products are formulated with ingredients to heal, relieve, protect, and repai
- Nivolumab Approved in Combination with Ipilimumabhttps://practicaldermatology.com/news/nivolumab-approved-in-combination-with-ipilimumab/2458859/The FDA has granted accelerated approval to nivolumab (Opdivo Injection, Bristol-Myers Squibb Company) in combination with ipilimumab for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. The clinical trial that supported approval randomized (2:1) 142
- Allergan Completes Acquisition of Kybella Maker Kytherahttps://practicaldermatology.com/news/allergan-completes-acquisition-of-kybella-maker-kythera/2458856/Allergan plc has successfully completed the acquisition of Kythera Biopharmaceuticals, Inc. Allergan acquired Kythera in an all-cash transaction valued at approximately $2.1 billion. The acquisition of Kythera adds Kybella® (deoxych
- Revance Therapeutics Initiates Phase 3 Clinical Trial of Botulinum Toxin Type A Topical Gel for Crow's Feethttps://practicaldermatology.com/news/revance-therapeutics-initiates-phase-3-clinical-trial-of-botulinum-toxin-type-a-topical-gel-for-crows-feet/2458857/Revance Therapeutics, Inc. has commenced dosing patients in the Phase 3 pivotal study to evaluate the safety and efficacy of its RT001 investigational topical drug product candidate for the treatment of lateral canthal lines, or crow’s feet. The Phase 3 trial will evaluate the safety and ef
- FDA Approves Juvederm® Ultra XC for Use in Lipshttps://practicaldermatology.com/news/fda-approves-juvederm-ultra-xc-for-use-in-lips/2458860/Allergan has received FDA approval to market Juvederm® Ultra XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21. It is the only dermal filler that has proven results lasting up to one year for lip augmentation
- Dermira: Kathleen Sebelius Elected to Board of Directorshttps://practicaldermatology.com/news/dermira-kathleen-sebelius-elected-to-board-of-directors/2458861/Dermira, Inc. has elected Kathleen Sebelius, the 21st U.S. Secretary of Health and Human Services, to its board of directors. "We are honored and excited to welcome Kathleen Sebelius to Dermira's board of directors,&quo